Identification and experimental validation of CD74, PGLYRP1, and TXN as potential biomarkers in rheumatoid arthritis: an integrative bulk and ScRNA-seq study - Top-Institutions - MDSpire

Identification and experimental validation of CD74, PGLYRP1, and TXN as potential biomarkers in rheumatoid arthritis: an integrative bulk and ScRNA-seq study

  • By

  • Yun Zheng

  • Tihui Wang

  • Jiyue Huang

  • Peng Niu

  • Xiu Yang

  • Jie Xiao

  • Guanyin Wu

  • Xiaotang Sun

  • Jinquan Li

  • Hui Wang

  • June 23, 2026

  • 0 min

Share

Top Institutions in Rheumatology

Brief introduction explaining scope and methodology.

  • #1

    Brigham and Women's Hospital
    Brigham and Women's Hospital

    Boston, Massachusetts

    Key Differentiators

    • Rheumatology

  • #2

    Hospital for Special Surgery
    Hospital for Special Surgery

    New York, New York

    Key Differentiators

    • Rheumatology

  • #3

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, Ohio

    Key Differentiators

    • Rheumatology

  • #4

    Mayo Clinic
    Mayo Clinic

    Rochester, Minnesota

    Key Differentiators

    • Rheumatology

  • #5

    Johns Hopkins Hospital
    Johns Hopkins Hospital

    Baltimore, Maryland

    Key Differentiators

    • Rheumatology

Original Source(s)

Identification and experimental validation of CD74, PGLYRP1, and TXN as potential biomarkers in rheumatoid arthritis: an integrative bulk and ScRNA-seq study

  • by Yun Zheng, Tihui Wang, Jiyue Huang, Peng Niu, Xiu Yang, Jie Xiao, Guanyin Wu, Xiaotang Sun, Jinquan Li, Hui Wang

  • June 23, 2026

Related Content

The time-effect relationship of intra-articular ozone injection for knee osteoarthritis: a systematic review and meta-analysis

Mechanisms outpacing medicine in autoinflammatory diseases

On-treatment change in bone turnover markers predicts 2-year bone mineral density after sequential therapy following romosozumab: a real-world cohort study